These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 29335533)
1. Fc-modified exenatide-loaded nanoparticles for oral delivery to improve hypoglycemic effects in mice. Shi Y; Sun X; Zhang L; Sun K; Li K; Li Y; Zhang Q Sci Rep; 2018 Jan; 8(1):726. PubMed ID: 29335533 [TBL] [Abstract][Full Text] [Related]
2. The use of low molecular weight protamine to enhance oral absorption of exenatide. Zhang L; Shi Y; Song Y; Sun X; Zhang X; Sun K; Li Y Int J Pharm; 2018 Aug; 547(1-2):265-273. PubMed ID: 29800739 [TBL] [Abstract][Full Text] [Related]
3. Tf ligand-receptor-mediated exenatide-Zn Zhang L; Shi Y; Song Y; Duan D; Zhang X; Sun K; Li Y J Drug Target; 2018 Dec; 26(10):931-940. PubMed ID: 29619854 [TBL] [Abstract][Full Text] [Related]
4. Utilization of PLGA nanoparticles in yeast cell wall particle system for oral targeted delivery of exenatide to improve its hypoglycemic efficacy. Ren T; Zheng X; Bai R; Yang Y; Jian L Int J Pharm; 2021 May; 601():120583. PubMed ID: 33839225 [TBL] [Abstract][Full Text] [Related]
5. Long-acting inhalable chitosan-coated poly(lactic-co-glycolic acid) nanoparticles containing hydrophobically modified exendin-4 for treating type 2 diabetes. Lee C; Choi JS; Kim I; Oh KT; Lee ES; Park ES; Lee KC; Youn YS Int J Nanomedicine; 2013; 8():2975-83. PubMed ID: 23976850 [TBL] [Abstract][Full Text] [Related]
6. The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles. Li X; Wang C; Liang R; Sun F; Shi Y; Wang A; Liu W; Sun K; Li Y Pharm Res; 2015 Mar; 32(3):1017-27. PubMed ID: 25270570 [TBL] [Abstract][Full Text] [Related]
7. Synthesis of CSK-DEX-PLGA Nanoparticles for the Oral Delivery of Exenatide to Improve Its Mucus Penetration and Intestinal Absorption. Song Y; Shi Y; Zhang L; Hu H; Zhang C; Yin M; Chu L; Yan X; Zhao M; Zhang X; Mu H; Sun K Mol Pharm; 2019 Feb; 16(2):518-532. PubMed ID: 30601014 [TBL] [Abstract][Full Text] [Related]
8. Novel PLGA-based nanoparticles for the oral delivery of insulin. Malathi S; Nandhakumar P; Pandiyan V; Webster TJ; Balasubramanian S Int J Nanomedicine; 2015; 10():2207-18. PubMed ID: 25848248 [TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres. Liu B; Dong Q; Wang M; Shi L; Wu Y; Yu X; Shi Y; Shan Y; Jiang C; Zhang X; Gu T; Chen Y; Kong W Chem Pharm Bull (Tokyo); 2010 Nov; 58(11):1474-9. PubMed ID: 21048339 [TBL] [Abstract][Full Text] [Related]
10. Oral delivery of exenatide-loaded hybrid zein nanoparticles for stable blood glucose control and β-cell repair of type 2 diabetes mice. Bao X; Qian K; Yao P J Nanobiotechnology; 2020 Apr; 18(1):67. PubMed ID: 32345323 [TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4. Wang M; Zhang Y; Feng J; Gu T; Dong Q; Yang X; Sun Y; Wu Y; Chen Y; Kong W Int J Nanomedicine; 2013; 8():1141-54. PubMed ID: 23658482 [TBL] [Abstract][Full Text] [Related]
12. Oral delivery system for low molecular weight protamine-dextran-poly(lactic-co-glycolic acid) carrying exenatide to overcome the mucus barrier and improve intestinal targeting efficiency. Song Y; Shi Y; Zhang L; Hu H; Zhang C; Yin M; Zhang X; Sun K Nanomedicine (Lond); 2019 Apr; 14(8):989-1009. PubMed ID: 31088322 [No Abstract] [Full Text] [Related]
13. Pharmacological Signatures of the Exenatide Nanoparticles Complex Against Myocardial Ischemia Reperfusion Injury. Zhang Y; Qian P; Zhou H; Shen R; Hu B; Shen Y; Zhang X; Shen X; Xu G; Jin L Kidney Blood Press Res; 2018; 43(4):1273-1284. PubMed ID: 30078011 [TBL] [Abstract][Full Text] [Related]
14. Nanoparticles with surface features of dendritic oligopeptides as potential oral drug delivery systems. Bai Y; Zhou R; Wu L; Zheng Y; Liu X; Wu R; Li X; Huang Y J Mater Chem B; 2020 Apr; 8(13):2636-2649. PubMed ID: 32129375 [TBL] [Abstract][Full Text] [Related]
15. Improved oral absorption of exenatide using an original nanoencapsulation and microencapsulation approach. Soudry-Kochavi L; Naraykin N; Nassar T; Benita S J Control Release; 2015 Nov; 217():202-10. PubMed ID: 26381898 [TBL] [Abstract][Full Text] [Related]
17. N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption. Sheng J; Han L; Qin J; Ru G; Li R; Wu L; Cui D; Yang P; He Y; Wang J ACS Appl Mater Interfaces; 2015 Jul; 7(28):15430-41. PubMed ID: 26111015 [TBL] [Abstract][Full Text] [Related]
18. Sustained-release study on Exenatide loaded into mesoporous silica nanoparticles: in vitro characterization and in vivo evaluation. Chen C; Zheng H; Xu J; Shi X; Li F; Wang X Daru; 2017 Sep; 25(1):20. PubMed ID: 28870261 [TBL] [Abstract][Full Text] [Related]
19. Preparation, evaluation, and Pan X; Liu S; Ju L; Xi J; He R; Zhao Y; Zhuang R; Huang J Drug Dev Ind Pharm; 2020 Nov; 46(11):1889-1897. PubMed ID: 32975456 [TBL] [Abstract][Full Text] [Related]
20. Folate-decorated PLGA nanoparticles as a rationally designed vehicle for the oral delivery of insulin. Jain S; Rathi VV; Jain AK; Das M; Godugu C Nanomedicine (Lond); 2012 Sep; 7(9):1311-37. PubMed ID: 22583576 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]